Open Menu

Product Pipeline

Apnimed is exploring novel oral therapeutics targeting sleep-related breathing diseases.

Program
Preclinical
Preclinical
Phase 1
Ph 1
Phase 2
Ph 2
Phase 3
Ph 3
AD109

(aroxybutynin + atomoxetine)

OSA

AD109

AD109 is an investigational oral therapy, a pill designed to target the underlying neuromuscular dysfunction in people living with mild, moderate, and severe obstructive sleep apnea (OSA). This novel treatment targets the hypoglossal motor nucleus (HMN) to increase signals in the upper airway dilator muscles during sleep to limit or prevent airway collapse.

 

AD109 was studied in the now-complete Phase 2b MARIPOSA trial and is currently being evaluated in two Phase 3 clinical trials, SynAIRgy and LunAIRo.

Close

Partnered Program

Program
Preclinical
Preclinical
Phase 1
Ph 1
Phase 2
Ph 2
Phase 3
Ph 3

Next-Generation Programs

As part of our joint venture with Shionogi & Co., Ltd, Shionogi Apnimed Sleep Science (SASS), we are developing novel oral combination therapeutics designed for people living with OSA and other sleep-related breathing diseases.

Close
The investigational product candidates on this page are not approved by the FDA and their safety and effectiveness have not been established.

We continue to advance our portfolio of pharmaceutical product
candidates designed to treat a broader range of sleep-related
breathing diseases.

A biological process for oxygenationA biological process for oxygenation

Innovation in OSA: AD109

Discover our paradigm-shifting investigational drug in development for OSA.

Learn About AD109
A doctor putting surface electrodes on a patientA doctor putting surface electrodes on a patient

Explore Apnimed Clinical Trials

Get information on current trials and see results for completed ones.

View Clinical Trials